TRS vs TSLA

TriMas Corporation presents a contradictory profile with a stable Piotroski F-Score of 4/9 and a strong 1-year price return of 90%, yet it suffers from severe fundamental deterioration. While the company maintains a healthy Debt/Equity ratio (0.74) and strong liquidity (Current Ratio 2.52), the massive YoY revenue decline of -31.80% and a negative operating margin (-3.38%) are critical concerns. The discrepancy between the Graham Number ($27.40) and the Intrinsic Value ($52.51) suggests the market is pricing in a recovery that is not yet supported by top-line growth. Overall, the stock is a speculative hold until revenue stabilizes.

Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.